In possibly its last major move for the time being to shed non-core assets following the acquisition of Shire Pharmaceuticals Group PLC, Takeda Pharmaceutical Company Limited. has confirmed it will sell its consumer health business in Japan to the major US private equity investor Blackstone Group, Inc.
Both the divestment and the emergence of Blackstone as a front-runner buyer had been rumored for some time, with a deal worth up to $2